TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
TCR2 Therapeutics Inc. (TCRR)
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Began dosing of TC-210 in the Phase 1/2 trial for patients with mesothelin-expressing solid tumors and an interim update anticipated in 4Q19/1Q20Leading clinical sites participating in the TC-210 trial include Sarah Cannon Research Institute, MD Anderson Cancer Center and the National Cancer InstituteIND filing for TC-110 in patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia anticipated in 2H19 CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced financial results for the second quarter ended June 30, 2019 and provided a corporate update. "In the second quarter of 2019, we made significant progress with our two lead programs TC-210 and TC-110," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "We began patient dosing in a Phase 1/2 cl
Show less
Read more
Impact Snapshot
Event Time:
TCRR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRR alerts
High impacting TCR2 Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
TCRR
News
- TCR2 Therapeutics Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TCRR/price-target/">NASDAQ: TCRR</a>) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $5.00 MarketBeat
- TCR2 Therapeutics Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TCRR/price-target/">NASDAQ: TCRR</a>) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.MarketBeat
- TCR2 Therapeutics Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TCRR/price-target/">NASDAQ: TCRR</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price tarMarketBeat
- TCR2 Therapeutics Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TCRR/price-target/">NASDAQ: TCRR</a>) had its price target lowered by analysts at HC Wainwright from $25.00 to $19.00.MarketBeat
- TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy OfficerGlobeNewswire
TCRR
Earnings
- 11/10/21 - Miss
TCRR
Sec Filings
- 1/12/22 - Form 4
- 1/12/22 - Form 3
- 12/10/21 - Form 4
- TCRR's page on the SEC website